Mode
Text Size
Log in / Sign up

Extended goal-directed fluid therapy shows no benefit for complications after esophagectomy in single-center trialDoes personalized fluid therapy after esophageal cancer surgery reduce complications?

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider that extended goal-directed fluid therapy did not reduce complications after esophagectomy in this small trial.

In a single-center, single-blind randomized controlled trial, 100 patients undergoing esophagectomy for esophageal cancer were assigned to receive either extended goal-directed fluid therapy or standard care. The intervention was individualized based on the patient's nighttime baseline cardiac output and mean arterial pressure thresholds and administered from tracheal intubation through to 7:00 am the following morning. The primary outcome was total postoperative morbidity measured by the Comprehensive Complication Index (CCI) at day 30.

The study found no difference in the primary outcome between groups (mean CCI: 39.0 ± 20.0 in the intervention group vs. 39.2 ± 21.0 in the standard group; mean difference -0.2, 95% CI -8.6 to 8.1, P = 0.95). Protocol adherence was demonstrated, with the intervention group having a higher mean fluid balance (mean difference 516 ml, 95% CI 57 to 974, P = 0.028), increased norepinephrine use (median 7,894 µg vs. 4,611 µg, P < 0.001), and a higher mean arterial pressure (mean difference 3 mmHg, 95% CI 1 to 5, P = 0.011).

Safety and tolerability data were not reported. Key limitations include the single-center design and small sample size of 100 patients. The study's practice relevance is restrained; while the protocol achieved its physiological targets, it did not translate to a reduction in postoperative complications. Funding and conflicts of interest were not reported.

When you're recovering from major surgery for esophageal cancer, every detail of your care matters. Doctors wondered if a more personalized approach to managing fluids and blood pressure overnight could help patients heal with fewer problems. They tested this idea in 100 patients, carefully adjusting fluids and medications to keep blood pressure at a patient's own nighttime baseline.

The study found that patients who received this extended, personalized therapy did get more fluids and needed more blood pressure medication (norepinephrine) to hit those targets. Their average blood pressure was slightly higher. But when researchers looked at the big picture—the overall burden of complications 30 days after surgery—there was no meaningful difference between the two groups.

This means that, in this specific hospital setting, hitting these personalized targets didn't translate into fewer complications for patients. It's an important finding, but we need to be careful. This was a relatively small study at just one hospital, so we don't know if the results would be the same elsewhere. The researchers didn't report on safety issues or side effects from the extra medication. For now, this personalized overnight approach shows promise in theory but didn't deliver the hoped-for benefit in practice.

What this means for you:
Personalized overnight fluid therapy after esophageal surgery didn't reduce complications in a single-hospital study.

Study Details

Study typeRct
Sample sizen = 1
EvidenceLevel 2
PublishedApr 2026
View Original Abstract ↓
BACKGROUND: Esophagectomy is a key treatment for esophageal cancer but carries a high risk of postoperative complications, some of which are potentially preventable through optimized hemodynamic management. Goal-directed fluid therapy individualizes cardiac output targets but often applies fixed blood pressure thresholds and is discontinued before major postoperative fluid shifts occur. Extending goal-directed fluid therapy into the postoperative period with individualized blood pressure thresholds may address these limitations. METHODS: In this single-center, prospective, blinded, randomized controlled trial, patients undergoing esophagectomy were randomized 1:1 to either extended goal-directed fluid therapy or standard care. In the extended goal-directed fluid therapy group, cardiac output was optimized and mean arterial pressure threshold was the individual patient's nighttime baseline. The protocol continued from tracheal intubation through to 7:00 am the following morning. The primary outcome was total postoperative morbidity, measured by the Comprehensive Complication Index at day 30. RESULTS: Of 100 patients (49 extended goal-directed fluid therapy group, 51 standard group), extended goal-directed fluid therapy was associated with a higher fluid balance (2,517 ± 1,194 ml vs. 2,001 ± 1,114 ml; mean difference, 516 ml; 95% CI, 57 to 974; P = 0.028), increased norepinephrine use (median, 7,894 μg [interquartile range, 3,946-13,793] vs. 4,611 μg [interquartile range, 2,138 to 7,296]; P < 0.001), and higher mean arterial pressure (mean difference, 3 mmHg; 95% CI, 1 to 5; P = 0.011). At day 30, the mean Comprehensive Complication Index did not differ between groups (39.0 ± 20.0 vs. 39.2 ± 21.0; mean difference, -0.2; 95% CI, -8.6 to 8.1; P = 0.95). CONCLUSIONS: Despite achieving protocol-driven treatment differences, extended and individualized goal-directed fluid therapy did not reduce postoperative complications after esophagectomy.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.